Ratings Illumina, Inc.

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-13 EDT			5-day change	1st Jan Change
86.93 ^USD	-1.36%		+5.17%	-34.95%

06-10	Illumina, Inc., Q1 2025 Earnings Call, May 08, 2025
05-29	Illumina Inc. Unveils PromoterAI, Groundbreaking Algorithm to Accelerate Insights for Rare Disease Diagnosis	CI

Summary: Illumina, Inc.

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to MSCI, the company's ESG score for its industry is good.

Highlights: Illumina, Inc.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Illumina, Inc.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
With a 2025 P/E ratio at 24.7 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
With an enterprise value anticipated at 3.16 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Illumina, Inc.

Source: Surperformance

ESG chart: Illumina, Inc.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ILLUMINA, INC.				13.76B
	INTUITIVE SURGICAL, INC.				184B
	THERMO FISHER SCIENTIFIC INC.				152B
	BOSTON SCIENTIFIC CORPORATION				148B
	DANAHER CORPORATION				144B
	SIEMENS HEALTHINEERS AG				58.85B
	EDWARDS LIFESCIENCES CORPORATION				44.08B
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.				39.96B
	RESMED, INC.				36.49B
	AGILENT TECHNOLOGIES, INC.				33.26B
	Average				85.32B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes